Rearrangements involving the anaplastic lymphoma kinase (ALK) gene are defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non-small cell lung carcinoma (NSCLC). In such cancers, the oncogenic activity of ALK stimulates signaling pathways that induce cell transformation and promote tumor growth. In search for common pathways activated by oncogenic ALK across different tumors types, we found that hypoxia pathways were significantly enriched in ALK-rearranged ALCL and NSCLC, as compared with other types of T-cell lymphoma or EGFR-and K-RAS-mutated NSCLC, respectively. Consistently, in both ALCL and NSCLC, we found that under hypoxic conditions, ALK directly regulated the abundance of hypoxia-inducible factors (HIF), which are key players of the hypoxia response in normal tissues and cancers. In ALCL, the upregulation of HIF1a and HIF2a in hypoxic conditions required ALK activity and its downstream signaling proteins STAT3 and C/EBPb. In vivo, ALK regulated VEGFA production and tumor angiogenesis in ALCL and NSCLC, and the treatment with the anti-VEGFA antibody bevacizumab strongly impaired ALCL growth in mouse xenografts. Finally, HIF2a, but not HIF1a, was required for ALCL growth in vivo whereas the growth and metastasis potential of ALK-rearranged NSCLC required both HIF1a and HIF2a. In conclusion, we uncovered an ALK-specific regulation of the hypoxia response across different ALK þ tumor types and propose HIFs as a powerful specific therapeutic target in ALK-rearranged ALCL and NSCLC. Cancer Res; 74(21); 1-13. Ó2014 AACR.
Introduction
The anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase involved in chromosomal rearrangements in anaplastic large-cell lymphoma (ALCL), non-small cell lung carcinoma (NSCLC; ref. 1) , and other solid cancers (2) . Frequently, in ALCL the Nucleophosmin 1 (NPM1) gene and ALK generate the NPM-ALK fusion, but more than 20 other partners of ALK have been cloned in ALCL (2) . In NSCLC, ALK rearrangements occur in 6% to 7% of the cases and mainly involve the echinoderm microtubule-associated protein-like 4 (EML4) gene as a partner (1) but additional ALK rearrangements have also been described previously (3, 4) .
The cell-transforming potential of ALK in tumors largely depends on its deregulated tyrosine kinase activity that results from spontaneous dimerization (2) . Several downstream pathways are activated by NPM-ALK, with a broad range of signals that lead to increased cell proliferation, survival, motility, and cytoskeletal rearrangements (2, 5) . In ALCL, ALK oncogenic signals are mediated by a series of key molecules and pathways, including STAT3, PI3K, RAS/MAPK/ERK, SHP2, p130CAS, PLCg, and Src (2, 5) . In NSCLC, conversely, downstream pathways are less extensively characterized (6) .
Early clinical trials have shown that ALK-rearranged tumors respond quite dramatically to the inhibition of the ALK activity by specific inhibitors such as crizotinib (5) . High rate of responses were observed in patients with ALK-rearranged NSCLC (7) and ALCL (8) . Unfortunately, the benefit of ALK inhibition is only transient because tumors relapse almost invariably in patients due to the development of resistance to crizotinib (9, 10) . Therefore, novel therapeutic targets are needed for potential combination therapies with ALK inhibitors.
Our group and others previously described a link between ALK and angiogenesis in lymphoma (11) and neuroblastoma (12) . In ALCL, oncogenic ALK was shown to control VEGF expression in vitro in murine cells and human ALCL (11, 13) . Furthermore, ALK-dependent regulation of platelet-derived growth factor receptor-b (PDGFRb) could contribute to tumor angiogenesis in a mouse model of ALK-rearranged lymphoma (14) . In neuroblastoma, ALK-deregulated activity controlled both tumor growth and tumor vessel formation (12) .
Tumor angiogenesis provides oxygen and nutrients to the growing mass (15) , and hypoxic conditions are critical to stimulate new vessel formation in tumors (16) . The regulators of hypoxic response in the cells are transcription factors called hypoxia-inducible factors (HIF). HIFs are heterodimers composed of an O 2 -labile a subunit (HIF1a, HIF2a, and the less characterized HIF3a) and a stable b subunit (HIF1b). Whereas HIF1a is ubiquitously expressed, HIF2a and HIF3a have a more restricted pattern of expression, including vascular endothelial cells and type II pneumocytes (17) . The role of HIFs in different cancer types is variable and sometimes contradictory, sharing redundant functions but also opposing effects on angiogenesis, metabolism, and other processes that can influence tumor growth (18) .
In the present study, we show that the hypoxia response is specifically enriched in a large series of human ALK-rearranged lymphoma and NSCLC cases, and we provide evidence that ALK specifically regulates HIF1a and HIF2a expression under hypoxia conditions in both ALCL and NSCLC. In vivo, ALK activity induced VEGF production and tumor angiogenesis and we demonstrated that HIF2a, but not HIF1a, was required for ALCL growth, whereas both HIF1a and HIF2a were essential for NSCLC growth and metastasis. Thus, we have identified an ALK-dependent hypoxic response shared by ALK-rearranged ALCL and NSCLC, and suggest VEGFA and HIFa proteins as powerful therapeutic targets for ALKrearranged tumors.
Materials and Methods
Gene-expression profiling and GSEA Gene-expression profiling (GEP) data from T-cell lymphomas were generated by our group (19) . Expression data for NSCLC are publicly available (20, 21) .
Cell lines and reagents
ALK-rearranged (TS, SU-DHL1, JB6, and Karpas-299) and ALK À (CEM, FePD, JURKAT, and MAC-1) ALCL cell lines were obtained from the DSMZ (German collection of Microorganisms and Cell Cultures) collection and were previously described (22) . Methods of characterization from the cell bank include karyotyping and DNA fingerprinting. Cells were passaged for fewer than 6 months after receipt and resuscitation. Cells were internally tested by ALK and p53 mutational status within 6 months after receipt and resuscitation. (23) . ALK-, C/EBPb-, and Stat3-specific shRNAs have been previously described (23, 24) . Retrovirus expressing NPM-ALK (25), STAT3C (26) or lentivirus expressing C/EBPb (23) have been previously described.
Immunoblotting
Total cellular proteins were extracted as previously described (22) . Primary antibodies used were: anti-HIF1a (1:800; Cell Signaling Technology), anti-HIF2a (1:800; Novus Biologicals), anti-ALK (1:2,000; Invitrogen), anti-phospho-ALK (1:1,000; Cell Signaling Technology), anti-actin (1:2,000; Sigma), anti-phospho-IKB (1:1,000; Cell Signaling Technology), anti-STAT3 (1:1,000; Cell Signaling Technology), anti-C/EBPb (1:1,000; Cell Signaling Technology), anti-EGFR (1:1,000; Cell Signaling Technology), anti-phospho-EGFR (Y1068; 1:1,000; Cell Signaling Technology), anti-ERBB2 (1:1,000; Cell Signaling Technology), and anti-phospho-ERBB2 (Y1221/1222; 1:1,000; Cell Signaling Technology).
Histology, immunohistochemistry, and immunofluorescence
The following primary antibodies were used: CD34 (clone MEC14.7; Santa Cruz Biotechnology), a-smooth muscle actin (clone 1A4; DakoCytomation), desmin (clone D33; DakoCytomation), VEGFA (clone 26503; R&D Systems), and Ki-67 (clone MIB-1; DakoCytomation). Positive cells were evaluated on randomly selected high power field (HPF; Â100 objective) using an Image Analysis software (Olympus Italia).
Quantitative real-time PCR
Total cDNA was synthesized as previously described (22) . Normalization was performed against the housekeeping genes murine actin for mouse samples and human RPLP0 for human samples according to the formula 2 ÀDDC t , where the DC t ¼ C t (threshold cycle) gene of interest-C t internal control, as indicated by the manufacturer. Primers used in quantitative realtime PCR (qRT-PCR) as indicated in Supplementary Table S1 .
Mice strains and in vivo xenograft and metastasis assays
Strains of mice used in this study include K-Ras LSLG12V (27) , TgEGFR L858R (28), B-Raf LmLV600E (29) , and EML4-ALK transgenic mice (C. Voena; submitted for publication).
For in vivo induction of inducible lentiviral constructs, we dissolved doxycicline hydrochloride (MP Biomedicals, 1 g/L) in the drinkable water. For ALK knockdown, samples were collected at 96 hours after induction to achieve the maximum before the induction of apoptosis (24) .
Statistical analysis
For GEP, we used false discovery rate (FDR) to calculate the statistical significance of enrichment scores. For the other experiments, statistical significance was calculated with the Student t test, and only values lower than 0.05 were considered significant.
Results
Hypoxia pathways are significantly enriched in ALKrearranged ALCL and NSCLC
In the search for pathways significantly enriched in ALKrearranged ALCL, we performed gene set enrichment analysis (GSEA) of GEP data in a series of 169 T-cell lymphoma cases, which included 54 ALCL samples (30 ALK-rearranged ALCL and 24 ALK À ALCL), 74 peripheral T-cell lymphoma NOS (PTCL-NOS), and 41 angioimmunoblastic T-cell lymphoma. We found that several GSEA hypoxia datasets were significantly enriched in ALCL, as compared with other T-cell lymphoma types ( Supplementary Fig. S1A-S1C ). Furthermore, when we further separated ALCL into ALK þ and ALK À cases, GSEA indicated that hypoxia pathways enrichment was significantly associated with ALK þ ALCL cases ( Fig. 1 and Supplementary Fig. S2 ), thus suggesting that the deregulated ALK activity in ALCL could be directly related to a hypoxia signature. We next asked whether hypoxia pathways were enriched also in other tumors expressing ALK translocations. We compared the GEP dataset from EML4-ALK-rearranged NSCLC with EGFR-mutated NSCLC, in which EGFR-L858R or EGFR-Del19 mutations aberrantly activate the EGFR tyrosine kinase receptor. Hypoxia pathways were significantly enriched in ALK-rearranged NSCLC as compared with EGFR-mutated cases in two independent GEP datasets (Supplementary Fig. S3 ; refs. 20, 21). Thus, we concluded that ALK rearrangements are associated with an enriched hypoxia signature in both ALCL and NSCLC.
ALK regulates HIFs expression in ALCL via STAT3-and C/EBPb-dependent transcription Because hypoxia pathways are largely dependent on the activity of HIFs, we asked whether ALK activity could control HIFs expression in human cell lines derived from patients with ALK-rearranged ALCL. In all NPM-ALK-rearranged ALCL cell lines tested (SU-DHL-1, TS, JB6, and KARPAS-299), levels of HIF1a and HIF2a were low in standard 21% oxygen conditions, but were strongly upregulated in hypoxic condition (1% oxygen; Fig. 2A (Fig. 2B ). When we treated ALK-rearranged ALCL with the specific ALK inhibitors TAE684 or crizotinib to block the kinase activity of the NPM-ALK fusion, ALK phosphorylation was strongly reduced and HIF1a and HIF2a protein levels were strongly reduced in both normoxic and hypoxic conditions ( Fig. 2A and Supplementary Fig. S4 ). In contrast, HIF1a expression was modestly and inconsistently reduced in ALK À lymphoma cell lines, possibly due to some nonspecific effects of ALK inhibitors (Fig. 2B ). To further confirm the role of ALK in HIFs expression, we also performed a genetic knockdown of ALK by shRNA. Again, efficient knockdown of ALK induced a marked reduction of both HIF1a and HIF2a protein levels ( Supplementary Fig. S5 ), thus supporting our conclusions that in ALK-rearranged ALCL the expression of both HIF1a and HIF2a in hypoxic conditions is specifically regulated by the activity of ALK. Furthermore, although HIF1a upregulation in hypoxic conditions was detectable in all lymphoma cell lines, HIF2a upregulation appeared to be a specific feature of ALK þ ALCL. To further support the ALK specificity of HIF2a regulation, we analyzed the expression levels of HIF2a in ALK þ ALCL compared with ALK À ALCL and other T-cell lymphoma. Indeed, HIF2a expression was significantly higher in ALK-rearranged ALCL as compared with the other T-cell lymphoma analyzed (Fig. 2C ). HIFa proteins are regulated in normoxic and hypoxic cells through various mechanisms that include proteasome-dependent degradation and transcription (16, 18, 30) . In well-oxygenated conditions, hydroxylation of HIFa subunits induces their proteosomal degradation by an E3 ubiquitin ligase, the von Hippel-Lindau protein (pVHL) complex. In contrast, in hypoxic conditions, HIFa proteins are stabilized by a decreased proteasome-dependent degradation. Therefore, we asked whether the low levels of HIFa proteins during ALK inhibition could be explained by an increased proteasome-dependent degradation. To test this hypothesis, we treated ALCL with the proteasome inhibitor MG132. The inhibition of the proteasome-dependent degradation by MG132 clearly stabilized the known degradation target phospho-IKBa but it was unable to restore high levels of HIFa proteins in ALCL treated with the ALK inhibitor, thus ruling out proteasome-dependent degradation as a major mechanism of ALK-dependent HIFa regulation ( Supplementary  Fig. S6 ).
Next, we asked whether ALK regulated HIFa proteins by a transcription-dependent mechanism. By qRT-PCR, ALCL cells treated with an ALK inhibitor showed a significant reduction of both HIF1a and HIF2a mRNA levels ( Fig. 2D) , thus indicating that ALK controls HIFa expression at a transcriptional level. Because we and others previously showed that both STAT3 and C/EBPb are key transcription factors in the oncogenic ALK signaling (2, 23, (31) (32) (33) , and STAT3 has been shown to regulate HIF1a transcription (13), we tested whether they could be involved in ALK-dependent HIFa protein regulation. In ALCL cells, shRNA-mediated knockdown of either STAT3 or C/EBPb resulted in a marked reduction of both HIF1a and HIF2a protein levels (Supplementary PPP4R1  S100A10  SLC2A1  TPD52L2  GAPDH  TUBB2C  MNAT1  TEAD4  BNIP3  PGK1  TANC2  CA12  TPI1  C200RF20  MTX1  CNIH4  ANGPTL4  PMSD2  TNS4   ALDOA   PSMA7  CDCA4  LDLR  RUVBL2  NDUFA4L2  VEZT  GMFB  SIP1  PSMB7  TRMT5  DPM2  ANKRD9  TPBG  RAN  IGF2BP2  PDZD11  VAPB  PTGFRN  MIF  C140RF156  NDRG1  C160RF74  SLC16A1  S100A3  BCAR1  PFKFB4  C160FR68  B4GALT2  RNPS1  NUDT15  GSS  PPARD  EIF2S1  AK3L1  HES2  NME1  SNX24  RNF24  TMEM30B  ECE2  MRPL14  CA9  CORO1C  ADORA2B  P4HA1  KCTD11  TMTC3  KRT17  IL8  HOMER1  ANKRD37  TFAP2C  SLC6A8  PLEKHG3  XPO5  COL4A5  SLCO1B3  PGF Research.
on April 14, 2017. © 2014 American Association for Cancer cancerres.aacrjournals.org Downloaded from HIF2a, but not HIF1a, is essential for tumor growth in ALCL As we showed that HIF1a and HIF2a are regulated by the ALK activity in ALK-rearranged ALCL, we next seek to establish their biologic roles in ALCL growth. In a previous in vitro study in ALKrearranged ALCL cell lines, HIF1a depletion has been shown to increase cell proliferation but to decrease VEGF synthesis (13), thus suggesting potentially contrasting effects for ALCL growth in vivo. Indeed, both HIF1a and HIF2a have been shown to possess contradicting roles in vitro and in vivo, mostly due to the different types of tumor analyzed (18, 30) . Therefore, we decided to test directly in vivo the role of HIF1a and HIF2a in ALKrearranged ALCL tumor growth by xenograft assays. We generated inducible lentiviral vectors to specifically knockdown HIF1a or HIF2a proteins upon treatment with doxycycline (Supplementary Fig. S10 ). When HIF1a was knocked down by treating mice with doxycycline, we did not observe any impairment of tumor growth in vivo as compared with control untreated mice ( Fig. 3A and C) , consistent with previous in vitro results (13) . In contrast, HIF2a knockdown strongly impaired the growth of ALCL tumors in vivo (Fig. 3B and D and Supplementary Fig. S11) . Remarkably, the knockdown of HIF1a or HIF2a did not reduce tumor growth in ALK À lymphomas (Supplementary Fig. S12 ).
Finally, when we induced the HIF2a knockdown in established tumors, they arrested their growth and partially regressed ( Fig.  3B and D, arrows) . In sum, our data show that ALK specifically regulated HIF2a levels in lymphoma cells and that HIF2a is essential for ALCL growth and maintenance in vivo.
ALK-mediated VEGFA production is a therapeutic target in ALCL The induction of hypoxia pathways mediated by ALK could contribute to the regulation of angiogenesis and metabolism of ALCL cells. Indeed, previous reports have shown that patients with ALK-rearranged ALCL have higher VEGFA levels than ALK À ALCL (11) , that ALK regulates VEGFA secretion in fibroblasts in vitro (11) , and that HIF1a contributes at least partially to VEGFA secretion (13) . However, it is not known whether ALK-dependent VEGFA secretion has a role on tumor angiogenesis in vivo and whether the therapeutic blockade of VEGFA could be an effective therapeutic approach in ALCL. To address these points, we first confirmed in vitro that VEGFA mRNA and protein levels are regulated by ALK also in ALCL (Supplementary Fig. S13 ). Next, we showed that expression of VEGFA was downregulated in ALCL when ALK was knocked down by specific shRNA in vivo (Fig. 4A-C) . Because VEGFA regulates tumor vessels formation (35), we expected that a reduced production of VEGFA would decrease the formation and the number of tumor vessels. Indeed, ALCL tumors in which ALK was knocked down, and therefore VEGFA was reduced, showed a significant decrease in tumor vessels, as measured by CD34, SMA, and Desmin stainings (Fig. 4D) . To exploit ALK-induced VEGFA production as a target for therapeutic strategy, we treated mice that received ALCL xenografts with the VEGFA blocking antibody bevacizumab that is currently used in several clinical trials for different cancer types (36) . Remarkably, ALCL tumors in mice treated with bevacizumab grew significantly slower than in control mice, thus indicating an important role for the ALK-dependent VEGFA production in ALCL growth (Fig. 4E) . The growth of ALK À lymphoma xenografts was also impaired by bevacizumab ( Supplementary Fig. S14 ), thus indicating that in ALK À lymphoma VEGFA secretion could be regulated by different mechanisms but still be important for tumor growth. We thus concluded that VEGFA production induced by oncogenic ALK regulates tumor vessels formation in ALCL and can be a potential target for ALCL therapy.
Oncogenic ALK regulates HIF1a and HIF2a and VEGFA expression in NSCLC We showed that hypoxia pathways are enriched also in other ALK-rearranged tumor such as EML4-ALK-rearranged NSCLC (Supplementary Fig. S3 ). Therefore, we asked whether oncogenic ALK regulated HIFa proteins and VEGF expression also in NSCLC. Treatment with DFX to mimic hypoxic conditions induced increased levels of both HIF1a or HIF2a in several NSCLC cell lines, including EML4-ALK-rearranged H2228 and H3122 (Fig. 5A) , K-Ras-mutated A549, H460, and H441 (Fig. 5B) , and EGFR-mutated H1975 and H3255 (Fig.  5C ), whereas the B-RAF-mutated cell line H1395 showed only HIF1a upregulation (Fig. 5D) ALK-rearranged H2228 and H3122 (Fig. 5A) . Consistently, ALK knockdown by specific shRNA reduced HIF1a or HIF2a upregulation under DFX treatment (Supplementary Fig. S15 ).
Given that in ALK-rearranged NSCLC, the EGFR family members are active and share common signaling pathways with ALK that can compensate for an inhibited ALK signaling (6, 37), we next investigated whether inhibition of EGFR signaling would affect HIF1a or HIF2a expression. In contrast with ALK inhibitors, HIF1a and HIF2a protein levels were minimally affected by treatment with gefitinib, an EGFRspecific inhibitor (Supplementary Fig. S16A ), or with lapatinib, a broader EGFR and ERBB2 inhibitor (Supplementary Fig.  S16B ). Overall, these data indicate a specific role for ALK in the regulation of HIF1a and HIF2a in ALK-rearranged NSCLC.
To further prove the specific role of oncogenic ALK in HIFa regulation, we studied HIFa expression in genetically engineered mice (GEM) harboring the most common mutations found in NSCLC. We compared HIF1a and HIF2a mRNA levels in tumors isolated from GEM carrying the EML4-ALK translocation or the K-Ras V12G , EGFR L858R , or B-Raf V600E mutations ( Supplementary Fig. S17A ). We observed high HIF1a expression in K-Ras-mutated tumors that confirmed previous observations that oncogenic K-Ras increases HIF1a expression likely by reactive oxygen species generation ( Fig. 5E; refs. 30, 38) . Strikingly, HIF1a transcripts in EML4-ALK tumors were almost as high as K-Ras-mutated tumors, and significantly higher than HIF1a transcripts in normal lung, EGFR L858R -or B-Raf V600E -mutated tumors (Fig. 5E ). When we analyzed HIF2a mRNA levels, as expected, we found high expression in normal lung given that HIF2a is highly expressed in vessels and alveolar type II pneumocytes (17) . Remarkably, EML4-ALK mice showed significantly higher HIF2a transcripts than all the other lung cancer genotypes (Fig. 5F) .
Consistent with these data on HIFa regulation mediated by ALK in NSCLC, in GEM models VEGFA levels were significantly higher in EML4-ALK than in K-Ras V12G -, EGFR L858R -, or B-Raf V600E -mutated tumors (Supplementary Fig. S17B ) and the inhibition of ALK decreased VEGFA expression in human NSCLC ( Supplementary Fig. S17C ), thus indicating a direct control of VEGFA by oncogenic ALK also in NSCLC, as we showed in ALCL.
HIF1a and HIF2a regulate tumor growth, vessel formation, and metastasis in ALK-rearranged NSCLC
We next wished to examine the functions of HIFa proteins in ALK-rearranged NSCLC growth and metastasis formation. Knockdown of both HIF1a and HIF2a did not have significant effect on cell growth in vitro (data not shown) but significantly impaired the growth of ALK-rearranged NSCLC xenografts in both H2228 and H3122 EML4-ALK NSCLC cell lines (Fig. 6A, C, E and G) . Reduced growth was associated with reduced proliferation, as determined Mean and SDs are calculated on the basis of six independent areas from at least six independent mice for the group; Ã , P < 0.05; ÃÃ , P < 0.005; ÃÃÃ , P < 0.001.
by Ki-67 stainings (Fig. 6B, D, F and H) . In contrast, in the K-Ras G12S -mutated NSCLC cell line HIF1a knockdown did not affect tumor growth or proliferation, whereas HIF2a knockdown slightly increased tumor growth ( Supplementary  Fig. S18 ), in accordance with previously published observations in K-Ras-mutated GEM (39) . In ALK-rearranged NSCLC xenografts, HIF1a or HIF2a knockdown induced a decrease in VEGFA production (Fig. 7A ) and tumor vessel formation (Fig. 7B) .
Finally, because ALK-rearranged NSCLCs are typically associated with advanced disease (stage IV; ref. 40 ) and metastatic spread, in particular liver metastasis (41) , and because HIFs have been described to regulate tumor metastasis formation in solid cancers (18), we tested the roles of HIFa proteins in metastatic assays in vivo. Strikingly, either HIF1a or HIF2a knockdown almost completely abolished the metastatic potential of ALK-rearranged NSCLC in the lungs and in the liver (Fig. 7C-F and Supplementary Fig. S19 ), thus indicating nonredundant functions of HIF1a or HIF2a in ALK-rearranged NSCLC metastasis formation.
Discussion
In the present study, we showed that the ALK activity specifically controls hypoxia pathways and tumor vessels formation in ALK-rearranged ALCL and NSCLC. Together with the evidences on the role of ALK in neuroblastoma tumor angiogenesis (12) , collectively these data support the concept that controlling the hypoxia response could be one major function of oncogenic ALK in various tumor types. Both HIF1a and HIF2a were potently regulated by ALK in hypoxic conditions in ALK þ ALCL. Of note, we propose that HIF2a regulation is a specific feature of ALK-rearranged ALCL, as ALK À ALCL and cell lines showed significantly lower levels of HIF2a and a lack of HIF2a regulation under hypoxic conditions. Remarkably, we showed that both STAT3 and C/EBPb transcription factors are required to sustain hypoxia-induced HIF2a upregulation in ALK-rearranged ALCL. Because HIF1a and HIF2a have unique and sometimes opposing functions in tumor biology (18) , their precise role as oncogenes or tumor suppressor cannot be predicted and needs validation in each tumor in vivo. For example, in a mouse model of K-Ras-mutated NSCLC, HIF2a deletion increased tumor progression, thus acting as a tumor suppressor rather than an oncogene (39) . In contrast, HIF2a supports tumor growth in renal cell carcinoma (42) . We showed that HIF1a was dispensable for ALCL growth, thus confirming previous results in vitro (13) , whereas HIF2a was required not only for ALCL growth but also for its maintenance. Because it has been shown that ALK regulates lymphoma proliferation by sustaining c-myc levels in ALCL (43) and that HIF2a regulates c-myc expression (44) , one intriguing possibility is that ALK could promote lymphoma proliferation by an HIF2a-mediated c-myc regulation. Importantly, in ALCL oncogenic ALK not only specifically regulated HIF2a but lymphoma cells were addicted to its functions, suggesting that HIF2a targeting could work as an additional therapeutic option for ALCL.
With striking similarities to ALK-rearranged ALCL, EML4-ALK rearranged NSCLC showed enriched hypoxia pathways when compared with NSCLC carrying other common driver mutations, such as EGFR and K-RAS mutation. Regulation of HIF1a and HIF2a in ALK-rearranged NSCLC was less potent but consistent with that observed in ALKrearranged ALCL. One possible explanation for such difference could be that rearranged ALK is expressed at higher levels in ALCL than in NSCLC (2, 45) . As a result, oncogenic ALK activity is more dominant in ALCL than in NSCLC in terms of signaling pathway activation. In contrast with ALCL, in which oncogenic ALK activity dominates the signaling, the ALK blockade results in a milder inhibition of the same downstream pathways and in milder biologic effects in NSCLC (46) . Indeed, STAT3 phosphorylation is only minimally impaired by ALK inhibitor treatment (10), whereas C/EBPb is not expressed in ALK-rearranged NSCLC (data not shown), indicating that other pathways are likely involved in HIFs regulation in NSCLC. In this context, it is known that several additional tyrosine kinases can contribute to the biology of ALK-rearranged NSCLC (9) . We excluded a role for EGFR family receptors by gefitinib or lapatinib treatment as well as for c-MET because the selective ALK inhibitor TAE684 or the specific ALK shRNA knockdown had similar effects to the dual ALK-MET inhibitor crizotinib but it is possible that other tyrosine kinases, such as PDGFR or c-KIT, or other signaling pathways active in NSCLC would partially compensate for ALK inhibition. This "by pass" compensation of the ALK activity is also a recurrent mechanism that explains resistance to ALK inhibitors in NSCLC cells (9) . Of note, knockdown of either HIF1a or HIF2a inhibited not only tumor growth but also metastasis formation in EML4-ALK-rearranged NSCLC, therefore indicating that, in contrast with ALCL, in ALK-rearranged NSCLC both HIFa proteins act as oncogenes and could serve as potential targets for therapy.
Oncogenic ALK activity is also required for VEGFA production by ALCL and NSCLC cells. ALK knockdown significantly reduced VEGFA production and vessel formation in tumors in vivo. EML4-ALK lung tumors in GEM had significantly higher levels of VEGFA as compared with EGFR-, K-Ras-, and B-Rafmutated tumors, thus reinforcing the specificity of the ALKhypoxia-angiogenesis axis. In ALCL, the mechanisms of ALKmediated VEGF regulation could be quite complex because ALK controls at least four factors that regulate VEGF expression, such as HIF1a, HIF2a, STAT3, and C/EBPb as well as miRNA-16 (11) . Single knockdown of each of these four factors did not significantly change VEGF expression (data not shown). To this end, more complex combinatorial knockdown experiments are needed to precisely unveil the mechanisms of ALK-mediated VEGF regulation.
Blockade of VEGFA by the VEGFA-specific antibody bevacizumab in ALCL reduced vessels formation and tumor growth, thus indicating a potential efficacy of antiangiogenic drugs in ALK-rearranged lymphoma. The use of bevacizumab in lymphoma patients is still under debate due to the limited efficacy and associated toxicities (47) and should be restricted to lymphoma types with proven efficacy (48) . In this context, Â20) . Histograms, the mean numbers of tumor foci counted in the entire lungs and livers of mice. Data are from six independent mice each group; Ã , P < 0.05; ÃÃ , P < 0.005.
our data indicate that patients with ALK-rearranged ALCL may indeed benefit with treatment with bevacizumab. In solid cancers, bevacizumab has been approved as treatment for several late-stage advanced metastatic cancers (35) . However, the rate of response to bevacizumab in NSCLC is still unpredictable for unclear reasons. It has been suggested that a stratification based on the molecular genetics of NSCLC could improve the efficacy of bevacizumab, possibly by restricting its use in NSCLC with selected genetic lesions (36, 49) . On the basis of the results of the present study, ALK-rearranged NSCLC could represent a subset of tumors that could mostly benefit from such antiangiogenic therapy.
In summary, in this work, we present evidences for an ALKdependent hypoxia-angiogenesis regulation in both ALCL and NSCLC. ALK regulates HIF1a and HIF2a, which in turn become essential for tumor growth. Thus, treatments aimed at blocking the ALK-driven VEGFA production in ALCL and NSCLC, or directly at targeting HIF2a in ALCL and both HIF1a and HIF2a in NSCLC, have potentials to become additional therapeutic strategies in ALK-rearranged tumors.
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